Inhibrx's (INBX) 'Data Disclosures Leave us Guessing' - Citizens

Citizens analyst Reni Benjamin reiterated a Market Perform rating on Inhibrx Biosciences (NASDAQ: INBX).

The analyst commented, "Inhibrx's limited data disclosures and lack of management communication leave us guessing. No new data raises doubts about response durability and strength. The company's claim of insufficient data maturity suggests either slow-emerging responses, limited benefit, or an impact on the PFS tails that require further follow-up. For INBRX-109, expansion cohorts in mCRC and ES are advancing, with mature PFS data expected in 2Q26."

For an analyst ratings summary and ratings history on Inhibrx Biosciences click here. For more ratings news on Inhibrx Biosciences click here.

Shares of Inhibrx Biosciences closed at $81.57 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• SpaceX files for 555.56M share IPO at $135/sh
• Genco Shipping urges shareholders to reject Diana's $24.80 takeover bid